Assistance Publique-hopitaux De Paris

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Sorbonne Université

Université Pierre Et Marie Curie (paris 6)

Institut Curie

Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet)

Other

Centre National De La Recherche Scientifique-cnrs

Inserm (institut National De La Sante Et De La Recherche Medicale)

Institut National De La Sante Et De La Recherche Medicale (inserm)

Icm-institut Du Cerveau Et De La Moelle Epiniere

Université Paris Descartes

Université Pierre Et Marie Curie

Cnrs

Eliane Piaggio

David Klatzmann

Patrice Cacoub

David Saadoun

Gilbert Bensimon

Claude Bernard

Sebastian Amigorena

Genevieve Almouzni

Michèle Rosenzwajg

Luigia Pace

Christel Goudot

Leticia Niborski

Hugo Daniel Lujan

Hugo Lujan

Guillaume Dorothee

Hugo Daniel Luján

Louis Perol

Pierre Aucouturier

Dylla Ait Ahmed

Michéle Rosenzwajg

Geneviève Almouzni

Michele Rosenzwajg

Guillaume DOROTHÉE

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Low dose IL-2 for treating autoimmune-related or inflammatory disorders

The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically hinds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

Immune cells defective for SUV39H1

The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders

Immune cells defective for Suv39h1

Use of low dose IL-2 for treating autoimmune&#x2014;related or inflammatory disorders

Use of low dose IL-2 for treating autoimmune related or inflammatory disorders

The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.

Boosting Treg cells for treating Alzheimer disease and related disorders

An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-IL2 response, peptides specifically recognized by anti-IL2 antibodies or IL-2-specific T cells of T1D, systemic lupus erythematosus, rheumatoid arthritis, Sj&#xf6;gren's syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.

IL-2 peptide derivatives, and uses thereof for the diagnosis and treatment of an autoimmune disease

The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such asparasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.

Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof

The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such assp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., insulin, glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.

Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery

Method for stimulating T lymphocytes with IL-2

Growing community of inventors

Paris, France

Eliane Piaggio